Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Groupon Inc GRPN

Groupon, Inc. is a scaled two-sided marketplace that connects consumers to merchants. The Company’s marketplace is accessible through its mobile applications and its websites, which are primarily localized groupon.com sites in 13 countries. It has two segments, North America and International, and in three categories, Local, Goods and Travel. Local category includes services from local and national merchants, and other local and national merchants, including things to do, beauty and wellness and dining, as well as other services. Goods category includes merchandise across multiple product lines, such as electronics, sporting goods, jewelry, toys, household items and apparel. Travel category features travel experiences at both discounted and market rates, including hotels, airfare and package deals covering both domestic and international travel. The customer can contact the merchant directly to make a travel reservation after purchasing a travel voucher from the Company.


NDAQ:GRPN - Post by User

<< Previous
Bullboard Posts
Next >>
Post by MiaLandon Jun 03, 2022 4:54am
84 Views
Post# 34728729

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance



FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


 
<< Previous
Bullboard Posts
Next >>